BR0215043A - Combinação de inibidores de protease citocroma p450 dependentes - Google Patents

Combinação de inibidores de protease citocroma p450 dependentes

Info

Publication number
BR0215043A
BR0215043A BR0215043-3A BR0215043A BR0215043A BR 0215043 A BR0215043 A BR 0215043A BR 0215043 A BR0215043 A BR 0215043A BR 0215043 A BR0215043 A BR 0215043A
Authority
BR
Brazil
Prior art keywords
combination
cytochrome
protease inhibitors
dependent protease
furanyl
Prior art date
Application number
BR0215043-3A
Other languages
English (en)
Inventor
Ronald Van Der Geest
Paul Stoffels
Cornelis Groen
Dirk Edward Desire Jochmans
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0215043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BR0215043A publication Critical patent/BR0215043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

"COMBINAçãO DE INIBIDORES DE PROTEASE CITOCROMA P~ 450~ DEPENDENTES". A presente invenção se refere a um método para melhora da farmacocinética de inibidores da protease de HIV contendo hexahidrofuro[2,3-b]furanila compreendendo administração, a um ser humano que precise da mesma, de uma combinação de uma quantidade terapeuticamente eficaz de um inibidor da protease de HIV contendo hexahidro-furo[2,3b]furanila e uma quantidade terapeuticamente eficaz de um inibidor da citocroma P~ 450~.
BR0215043-3A 2001-12-12 2002-12-12 Combinação de inibidores de protease citocroma p450 dependentes BR0215043A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204841 2001-12-12
PCT/EP2002/014277 WO2003049746A2 (en) 2001-12-12 2002-12-12 Combination of cytochome p450 dependent protease inhibitors

Publications (1)

Publication Number Publication Date
BR0215043A true BR0215043A (pt) 2004-11-03

Family

ID=8181408

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215043-3A BR0215043A (pt) 2001-12-12 2002-12-12 Combinação de inibidores de protease citocroma p450 dependentes

Country Status (27)

Country Link
US (1) US20050119338A1 (pt)
EP (1) EP1458447B1 (pt)
JP (1) JP2005511723A (pt)
KR (1) KR100974921B1 (pt)
CN (1) CN100335060C (pt)
AR (1) AR037797A1 (pt)
AT (1) ATE442189T1 (pt)
AU (1) AU2002358713B2 (pt)
BR (1) BR0215043A (pt)
CA (1) CA2469343C (pt)
CY (1) CY1110604T1 (pt)
DE (1) DE60233677D1 (pt)
DK (1) DK1458447T3 (pt)
ES (1) ES2333206T3 (pt)
HR (1) HRP20040619A2 (pt)
HU (1) HUP0402644A3 (pt)
IL (1) IL162353A0 (pt)
MX (1) MXPA04005755A (pt)
NO (1) NO20042666L (pt)
NZ (1) NZ533826A (pt)
PL (1) PL373072A1 (pt)
PT (1) PT1458447E (pt)
RU (1) RU2329050C2 (pt)
SI (1) SI1458447T1 (pt)
TW (1) TWI286476B (pt)
WO (1) WO2003049746A2 (pt)
ZA (1) ZA200404633B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414916A (pt) * 2003-09-30 2006-11-07 Tibotec Pharm Ltd métodos para a preparação de compostos de sulfonamida de benzoxazol e intermediários dos mesmos
US20070104740A1 (en) * 2003-12-23 2007-05-10 Voorspoels Jody Firmin M Self-microemulsifying drug delivery systems of a hiv protease inhibitor
US7378441B2 (en) * 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
WO2006005720A1 (en) * 2004-07-08 2006-01-19 Tibotec Pharmaceuticals Ltd. Combination of anti-hiv reverse transcriptase and protease inhibitors
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
EP2842559A3 (en) * 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
AR057182A1 (es) 2005-11-28 2007-11-21 Tibotec Pharm Ltd Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
TWI432438B (zh) 2005-11-28 2014-04-01 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
AU2007285759B2 (en) 2006-08-18 2013-11-21 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome P450
EP2139883A4 (en) * 2007-03-23 2011-06-22 Univ Massachusetts HIV-1 protease inhibitor
UA103013C2 (uk) 2007-12-06 2013-09-10 Тиботек Фармасьютикелз Амідні сполуки як активатори противірусних препаратів
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
ES2572631T3 (es) 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
EP2346842A1 (en) 2008-10-07 2011-07-27 Tibotec Pharmaceuticals New amide compounds as boosters of antivirals
EP2429290B1 (en) * 2009-05-11 2014-01-01 Purdue Research Foundation Compounds and methods for treating aids and hiv infections
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP2576544A4 (en) * 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
EP2729130B1 (en) 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
SI2729128T1 (sl) 2011-07-07 2016-11-30 Janssen Sciences Ireland Uc Formulacije darunavirja

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010281A1 (en) * 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2262900A1 (en) * 1996-08-05 1998-02-12 Molecumetics Ltd. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
CA2872424C (en) * 1998-06-23 2017-03-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
TNSN00027A1 (fr) * 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
JP4814427B2 (ja) * 1999-02-12 2011-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼのインヒビター

Also Published As

Publication number Publication date
RU2004121144A (ru) 2005-04-20
TWI286476B (en) 2007-09-11
WO2003049746A2 (en) 2003-06-19
PT1458447E (pt) 2009-12-16
TW200409624A (en) 2004-06-16
EP1458447A2 (en) 2004-09-22
HUP0402644A3 (en) 2008-04-28
CA2469343A1 (en) 2003-06-19
CA2469343C (en) 2008-05-13
KR20040071182A (ko) 2004-08-11
ES2333206T3 (es) 2010-02-18
US20050119338A1 (en) 2005-06-02
ATE442189T1 (de) 2009-09-15
ZA200404633B (en) 2005-09-01
CN1604803A (zh) 2005-04-06
AR037797A1 (es) 2004-12-01
DK1458447T3 (da) 2010-01-18
AU2002358713A1 (en) 2003-06-23
PL373072A1 (en) 2005-08-08
IL162353A0 (en) 2005-11-20
JP2005511723A (ja) 2005-04-28
RU2329050C2 (ru) 2008-07-20
NO20042666L (no) 2004-09-09
CN100335060C (zh) 2007-09-05
WO2003049746A3 (en) 2003-12-31
AU2002358713B2 (en) 2009-01-29
MXPA04005755A (es) 2004-09-10
KR100974921B1 (ko) 2010-08-09
HK1070008A1 (en) 2005-06-10
SI1458447T1 (sl) 2010-01-29
NZ533826A (en) 2006-04-28
HUP0402644A2 (en) 2007-02-28
EP1458447B1 (en) 2009-09-09
CY1110604T1 (el) 2015-04-29
HRP20040619A2 (en) 2005-08-31
DE60233677D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
BR0215043A (pt) Combinação de inibidores de protease citocroma p450 dependentes
DK2295052T3 (da) Anvendelse af ritonavir til forbedring af farmakokinetikken af lægemidler, der metaboliseres af cytochrom P450
CY1120138T1 (el) Στερεη φαρμακευτικη μορφη δοσολογιας που περιλαμβανει μια στερεη διασπορα αναστολεα πρωτεασης toy hiv
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ECSP034922A (es) Pirrolopirimidinas
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
NO20013469L (no) Fremgangsmåter for glukagonsuppresjon
ATE504294T1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
PA8523201A1 (es) Nueva composicion farmaceutica
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
HUP0303838A2 (hu) Eritropoietin mérsékli a kemoterápia-indukált toxicitást in vivo
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
WO2004002491A8 (en) Morpholine and tetrahydropyran drivatives and their use as cathepsin inhibitors
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
SE0000303D0 (sv) Novel compounds
IL179544A0 (en) Compositions comprising flavonoids and tocotrienols and methods thereof
SV2003001422A (es) "1,3-diarilprop-2-en-1-onas,composiciones que las contienen y su utilizacion"
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
BR0001144B1 (pt) Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
BRPI0506498A (pt) composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450
WO2010033219A3 (en) Protease inhibitors having enhanced features

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 020130038104/RJ DE 06/05/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/635 (2006.01), A61P 31/18 (2006.01)